Status:
UNKNOWN
Ivermectin in Treatment of COVID-19
Lead Sponsor:
Zagazig University
Conditions:
COVID
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
confirmed cases with COVID-19 will receive ivermectin as a therapeutic option as well as standard of care treatment and will be compared to those that will receive only standard of care ttt
Eligibility Criteria
Inclusion
- COVID-19 patients during period of the study more than 18 years old
Exclusion
- refuse to participate pregnancy or lactation hypersensitivity to ivermectin receive any drug with interaction with ivermectin
Key Trial Info
Start Date :
May 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 15 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04445311
Start Date
May 31 2020
End Date
August 15 2020
Last Update
June 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Waheed Shouman
Zagazig, Sharqia Province, Egypt, 44519